Company profile

Jiangsu Hengrui Pharmaceuticals

Diversified pharma

600276 · SSE · China

Public Market Listing

600276SSE

SSE primary exchange listing

Live quotes, historical charts, and market capitalization for Jiangsu Hengrui Pharmaceuticals are available on Yahoo Finance.

View quote & market cap on Yahoo Finance ↗

External market data link · No third-party exchange redistribution

Assets

(55 total)
55Total Assets
0Approved
23Phase 3 / Filed
32Phase 1–2 / Early
17Diseases
Quick filter:
Showing 55 of 55 assets
Target & Modality
Adebrelimab
Phase 3
PD-L1Monoclonal antibody
Non-Small Cell Lung Cancer
Apatinib
Phase 3
VEGFR2Small molecule
Non-Small Cell Lung Cancer
Camrelizumab
Phase 3
PD-1Monoclonal antibody
Non-Small Cell Lung Cancer
Camrelizumab Famitinib
Phase 3
PD-1 (camrelizumab) plus VEGFR2/PDGFR-β/c-Kit (famitinib)Small molecule
Non-Small Cell Lung Cancer
Dalpiciclib
Phase 3
CDK4 and CDK6Small molecule
HR+/HER2- Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Famitinib
Phase 3
c-Kit, VEGFR2 (KDR), PDGFRbeta, VEGFR3, FLT1, FLT3Small molecule
Non-Small Cell Lung Cancer
Henagliflozin
Phase 3
Undisclosed / early pipeline · DPP-4Small molecule
Type 2 Diabetes
HR17031
Phase 3
Insulin receptor / GLP-1 receptor (combination)Peptide
Type 2 Diabetes
HRG2010
Phase 3
Undisclosed / early pipelineSmall molecule
Parkinson's Disease
HRS-7535
Phase 3
GLP-1 receptorSmall molecule
ObesityType 2 DiabetesHypertensionHeart Failure
INS068
Phase 3
Insulin receptor (basal)Peptide
Type 2 Diabetes
Noiiglutide
Phase 3
GLP-1 receptorPeptide
Type 2 Diabetes
PEX168No recent activity
Phase 3
GLP-1 receptorPeptide
Type 2 Diabetes
Pyrotinib
Phase 3
EGFR/HER1, HER2, HER4Small molecule
Non-Small Cell Lung Cancer
Recaticimab
Phase 3
PCSK9Monoclonal antibody
Atherosclerotic Cardiovascular Disease

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.